Clinical Trials Browser

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Stomach Neoplasms

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Stomach Neoplasms

Esophageal Neoplasms, Stomach Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Stomach Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Adenocarcinoma, Neoplasms, Stomach Neoplasms

Adenocarcinoma, Neoplasms, Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Adenocarcinoma, Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Stomach Neoplasms

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Adenocarcinoma, Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Stomach Neoplasms

Stomach Neoplasms

Recurrence, Stomach Neoplasms

Stomach Neoplasms

Adenocarcinoma, Neoplasm Metastasis, Stomach Neoplasms

Clinical Trials

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

STAR-221

HERIZON-GEA-01

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

FAPI-GO

KEYNOTE-585

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

KEYNOTE-585

KEYNOTE-859

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

FORTITUDE-101

Spotlight

GLOW

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

FORTITUDE-102

MK-3475-811

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

CheckMate649

A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

A Safety and Efficacy Study in Patients With Gastric Cancer

DIGEST

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

DREAM

Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer

Study of Adjuvant ONO-4538 With Resected Gastric Cancer

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

PRODIGY

BRIGHTER

MK-3475-062

MK-3475-063

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

ANGEL

MK-3475-061

A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer

SOLAR

KEYNOTE-859

HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

JACOB

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

GAMMA-1

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma